Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects
Related Experiment Video
Updated: Oct 3, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
Published on: June 5, 2017
1Institute of Clinical Pharmacology, Nanjing Medical University, Nanjing 210029, China. weimincai@hotmail.com
Aim:
To study the simultaneous modeling of pharmacokinetics and pharmacodynamics (PK-PD) of propafenone (Pro) in healthy subjects.
Methods:
Ten healthy Chinese volunteers, 5 extensive metabolizers (EM) and 5 intermediate metabolizers (IM) of CYP2D6, received a single dose (400 mg) of Pro hydrochloride. The blood samples and electrocardiogram (ECG) measurements were taken after administration over 15 h period. The concentrations of Pro in plasma were measured by a reverse-phase HPLC. PR interval was used as an average value of 10 PR interval measurements.
Results:
There was a delay between Pro level and percentage of PR interval prolongation. After PK-PD simulating, the relationship between effect concentration (Ce) and the effect met the sigmoid E(max) model. CYP2D6 (EM & IM) played an important role in both pharmacokinetics and pharmacodynamics which produced by Pro. The AUC (microg . h . L-1) of IM group was significantly higher than that of EM group (5126 +/- 1030 vs 2948 +/- 1230, P < 0.05). Whereas Ce50 (microg/L) was also greater in IM group than in EM group (747 +/- 281 vs 359 +/- 123, P < 0.05). On the other hand, gamma of EM group was about one fold larger than that of IM group (P < 0.05).
Conclusion:
CYP2D6 phenotype of human may influence not only pharmacokinetic of Pro but also its pharmacological effects.
Related Concept Videos
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
